PRMT6 overexpression has been reported recently in several types of cancers, including melanoma 24 and bladder and lung cancers 25, suggesting that inhibition of PRMT6 might be a promising new strategy for therapeutic intervention. Here, PRMT6 is linked to lung carcinoma.